HBM contact: Dr Ivo Staijen, Dr Emil Bujak
Company status: public
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio harnesses its proprietary antibody library to select antibodies against clinically relevant targets. Lead asset is in Phase 2 in Allergy/Autoimmunity covering indications such as Peanut allergy, Atopic dermatitis and Psoriasis. The company has a number of partnerships with biotechs such as Celgene and Tesaro.